These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

644 related items for PubMed ID: 16357613

  • 1. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
    Schröder O, Blumenstein I, Stein J.
    Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
    [Abstract] [Full Text] [Related]

  • 2. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG.
    Cochrane Database Syst Rev; 2012 Dec 12; 12():CD003459. PubMed ID: 23235598
    [Abstract] [Full Text] [Related]

  • 3. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG.
    Cochrane Database Syst Rev; 2014 Aug 06; 2014(8):CD003459. PubMed ID: 25099640
    [Abstract] [Full Text] [Related]

  • 4. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.
    Schröder O, Blumenstein I, Schulte-Bockholt A, Stein J.
    Aliment Pharmacol Ther; 2004 Feb 01; 19(3):295-301. PubMed ID: 14984376
    [Abstract] [Full Text] [Related]

  • 5. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I, Faubion WA.
    Inflamm Bowel Dis; 2012 Aug 01; 18(8):1488-92. PubMed ID: 21882301
    [Abstract] [Full Text] [Related]

  • 6. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM, Perry CM.
    BioDrugs; 2002 Aug 01; 16(2):111-48. PubMed ID: 11985485
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Infliximab in treatment of Crohn's disease: the Milan experience.
    Ardizzone S, Colombo E, Maconi G, Bollani S, Manzionna G, Petrone MC, Bianchi Porro G.
    Dig Liver Dis; 2002 Jun 01; 34(6):411-8. PubMed ID: 12132788
    [Abstract] [Full Text] [Related]

  • 12. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
    Kinney T, Rawlins M, Kozarek R, France R, Patterson D.
    Am J Gastroenterol; 2003 Mar 01; 98(3):608-12. PubMed ID: 12650795
    [Abstract] [Full Text] [Related]

  • 13. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May 01; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 14. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease.
    Kierkuś J, Iwańczak B, Wegner A, Dadalski M, Grzybowska-Chlebowczyk U, Łazowska I, Maślana J, Toporowska-Kowalska E, Czaja-Bulsa G, Mierzwa G, Korczowski B, Czkwianianc E, Żabka A, Szymańska E, Krzesiek E, Więcek S, Sładek M.
    J Pediatr Gastroenterol Nutr; 2015 May 01; 60(5):580-5. PubMed ID: 25564804
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
    Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.
    Aliment Pharmacol Ther; 2002 Oct 01; 16(10):1761-70. PubMed ID: 12269969
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
    Sabate JM, Villarejo J, Lemann M, Bonnet J, Allez M, Modigliani R.
    Aliment Pharmacol Ther; 2002 Jun 01; 16(6):1117-24. PubMed ID: 12030953
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.